Contact

Parkinson's disease: a breakthrough thanks to gene therapy

Parkinson's disease: a breakthrough thanks to gene therapy

A Franco-British team (AP-HP, INSERM, UPEC, CEA / MIRCen, Oxford Biomedica, Cambridge University) conducted a Phase I-II gene therapy clinical trial in patients with an advanced form of Parkinson’s disease.

Click here to learn more

MIRCen acquired a new Magnetic resonance imaging (MRI) scanner (11,7 Teslas) dedicated to rodents

MIRCen, preclinical research platform on neurodegenerative diseases located in Fontenay-aux-Roses, has just acquired a new Magnetic resonance imaging (MRI) scanner dedicated to rodents.

 

Read more...

Kick off Meeting de NeurATRIS (2)

Kick off Meeting de NeurATRIS, Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences

Kick off Meeting de NeurATRIS

Kick off Meeting de NeurATRIS